CORRESPONDENCE
We read with great interest the Review by Martinelli et al. (Inherited risk factors for venous thromboembolism. Nat. Rev. Cardiol. 11, 140-156 [2014] ), 1 which highlighted the main causes of inherited thrombophilia, their clinical manifestations, and the impli cations for antithrombotic prophylaxis. The Review was highly appreciated. However, whereas venous thromboembolism (VTE) is a dynamic, multifactorial disorder that results from the interaction between acquired and inherited factors, some important evidence that supports a role of HIV infection as a permanent, acquired risk factor for VTE was not included. Therefore, we wish to discuss the important impli cations of HIV infection in the accurate assessment of the absolute risk of VTE in patients with inherited thrombophilia.
Current epidemiological data suggest that chronic HIV infection is associated with a twofold to tenfold increase in the risk of VTE.
2,3 Furthermore, this elevated risk was confirmed in a large cohort study, with the highest rate in patients with both hepatitis C virus (HCV) and HIV. 4 The pathogenesis of this infectionassociated hypercoagulable state is associated with both the ongoing, unresolved, chronic inflammation and the chronic immune activation. 5 Indeed, several experimental studies have shown upregulation of tissue factor owing to direct or indirect monocyte activation, increased thrombin generation, increased platelet pro duction and activation, severe endothelial dysfunction and reduced nitric oxide pro duction, and a cytokineinduced decline in liver function resulting in a procoagulant state.
2,5,6 Treatment of HIV with combina tion antiretroviral therapy (cART) improves coagulation homeostasis and reduces viral replication, inflammation, and immune activation. cART often restores the peripheral CD4 + Tcell count and reduces viral repli cation, but inflammation, immune dys func tion, and coagulation abnormalities persist and strongly predict the risk of nonAIDS HIV infection as a permanent, acquired risk factor for VTE Michele Bibas, Gianluigi Biava and Andrea Antinori disorders. 7, 8 The risk of VTE also depends on the treatment of specific coinfections frequently observed in these patients, such as tuberculosis, Cytomegalovirus, and HCV, which contribute to the inflammatory e nvironment during cART.
9
Increasing age is one of the main acquired risk factors for VTE.
1 Interestingly, the profile of HIVassociated changes in markers of inflammation and coagulation are very similar to those reported with ageing and increased frailty in the general population (including a decline in endothelial nitric oxide production; increased platelet acti vation; and increased levels of ddimer, factors VIII, IX, and XI, fibrinogen, IL6, and von Willebrand factor).
5,10-12 Considerable attention should be given to the evidence that patients with HIV infection age more rapidly than individuals without HIV infec tion. 13 The phenomenon of accelerated immune ageing is also supported by the observation of earlier onset of agerelated morbidities in those with HIV infection, including VTE, than in individuals without HIV infection. 8, 13, 14 Furthermore, the risk of cardiovascular events is expected to increase substantially as patients with HIV infection live to older ages. Taken together, the hyper coagulable state associated with HIV infec tion and with other chronic infections, such as tuberculosis and HCV, must be considered as a permanent risk factor for VTE. Finally, in our view, many patients with mild thrombo philia, considered to be at low risk of VTE on the basis of chronological age and i nherited risk factors, should be considered to be at increased risk when infected with HIV, par ticularly if chronically coinfected with HCV, with important implications for prophylaxis and extended treatment of VTE.
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